There are 26 records that matched your search criteria

Date Title Category
14-Jun-2011 Joint MyIPO-PhAMA Seminar on '1 Malaysia Medicines: The Way Forward in Intellectual Property'
MyIPO Office, Level 12A, Menara UOA, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur
14-Jun-2011 MyIPO-PhAMA IP Seminar on Intellectual Property: 'The Way Forward' - Post event Videos and Photos
The MyIPO-PhAMA IP Seminar on Intellectual Property: "The Way Forward", was held on Tuesday 14 June 2011 at the...
24-Mar-2016 44th PhAMA Annual General Meeting 2016
13-Oct-2009 Caution Statement on “Severe Drug Interaction Between Colchicine and P-Glycoprotein or Strong CYP3A4 Inhibitors” required to be included in the product package insert for Colchicine
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
13-Oct-2009 Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential for an Increase in Risk of Suicidal Thoughts or Behaviours” required to be included in the product package insert for Antiepileptik.
Bil (43) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
12-Nov-2009 8th List for BE Studies for Oral “Immediate Release” Generic Products
Bil (46) dlm. BPFK/PPP/01/03 dated 30th October 2009
DCA letters
14-Apr-2010 Rules and regulation drug control regulations and cosmetics 1984 (Amendment 2006). Instruction numbers for two years in 2010. NPCB Circular on
Bil (49) dlm. BPFK/PPP/01/03 dated 14th April 2010
DCA letters
16-Aug-2010 Cosmetic products that are use around the eye and packaging that are not permitted for the product.
Bil (40) dlm. BPFK/17/K/2.2 dated 16th Aug 2010
DCA letters
14-Sep-2010 Products use on the male/female genitals for sexual purposes which is not categories as cosmetic classification
Bil (41) dlm. BPFK/17/K/2.2 dated 14th Sept 2009
DCA letters
25-May-2010 The Full evaluation launch module of QUEST3
Bil (45) dlm. BPFK/PPO/03/02 Bhg 3 dated 25th May 2010
DCA letters
22-Jul-2010 The statement warned: "Contraindicated In Children Under 2 Years of Age" that must be filled in the package insert of all products carbocysteine, acetylcarbocysteine and methylcarbocysteine (Mecysteine)
Bil (54) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010
DCA letters
22-Jul-2010 Caution Statement on "Boxed warning" must include Propylthiouracil with "Severe Liver Injury"
Bil (55) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010
DCA letters
23-Feb-2011 PhAMA Annual Games 2011
General News
23-Feb-2011 PhAMA 39th AGM Notice - 31 March 2011
General News
23-Feb-2011 Briefing on 'Competition Act 2010'
by the Ms Shila Dorai Raj, Director of the Interim Competition Commission, MDTCC
General News
23-Feb-2011 PhAMA: NKEA - Pemandu Steering committee mtg - 22nd Feb 2011 @ 10 a.m
General News